Dinara Il'GIzarovna Sadykova

Dinara Il'GIzarovna Sadykova

Auto-generated profile, based on publicly available information

Dinara Il'GIzarovna Sadykova

Kazan State Medical University

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2019 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
MYM. V. Yezhov
M. V. Yezhov
SBS. A. Bliznyuk
S. A. Bliznyuk
NTNarek Tmoyan
Narek Tmoyan
TRT. A. Rozhkova
T. A. Rozhkova
Dmitry V. DuplyakovDmitry V. Duplyakov
Dmitry V. Duplyakov
ТКТ. Ю. Кузнецова
Т. Ю. Кузнецова
Регистр пациентов с семейной гиперхолестеринемией и пациентов очень высокого сердечно-сосудистого риска с недостаточной эффективностью проводимой гиполипидемической терапии (РЕНЕССАНС)

16 July 2021 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
Marat EzhovMarat Ezhov
Marat Ezhov
OBOlga Barbarash
Olga Barbarash
MVMikhail Voevoda
Mikhail Voevoda
VGV. S. Gurevich
V. S. Gurevich
NVN. N. Vezikova
N. N. Vezikova
SBSergey Boytsov
Sergey Boytsov
Project of the Russian National Atherosclerosis SocietyIn 2016, Guidelines on the medical care organization to the patients with hereditary atherogenic lipid disorders in the regions of Russia were published, which described and presented the principles of routing patients with hereditary dyslipidemia and the organization of medical care for them within the current regulatory documents. In December 2018, the Russian Ministry of Health approved clinical guidelines for the diagnosis and treatment of familial hypercholesterolemia. Thus, persons with a severe hereditary dyslipidemia were able to get free medication with expensive lipid-lowering drugs and receive apheresis. Following the European ones, the Russian guidelines on the management of lipid metabolism disorders were updated: lower target low density lipoprotein cholesterol levels were adopted. In the Russian population, there is a high prevalence of hypercholesterolemia, including familial monogenic and polygenic types. Therefore, timely detection and routing to a lipid center or an office to a specialist (cardiologist, lipidologist), adequate and modern prescription of lipid-lowering therapy will make an important contribution not only to secondary, but also to primary prevention of atherosclerotic cardiovascular complications.

7 September 2019 in Pediatric pharmacology
Verified
Journal Article
Open access
PDF file
IKIgor A. Khamnagadaev
Igor A. Khamnagadaev
LSLilia I. Svintsova
Lilia I. Svintsova
TKTatiana K. Kruchina
Tatiana K. Kruchina
DSDinara I. Sadykova
Dinara I. Sadykova
DSDina R. Sabirova
Dina R. Sabirova
ЗХЗ. Р. Хабибрахманова
З. Р. Хабибрахманова
Суправентрикулярные (наджелудочковые) тахикардии у детей

10 October 2023 in Eurasian heart journal
Verified
Journal Article
Open access
PDF file
OKO. A. Kislyak
O. A. Kislyak
ILI. V. Leontyeva
I. V. Leontyeva
ASAntonina Vladimirovna Starodubova
Antonina Vladimirovna Starodubova
AAA. A. Alersandrov
A. A. Alersandrov
MBMarina G. Bubnova
Marina G. Bubnova
SUS. A. Ushakova
S. A. Ushakova
The EAC Guidelines represent the views of the EAC, and were produced after careful consideration of the scientific and medical knowledge, and the evidence available at the time of their publication.

6 July 2023 in Current Pediatrics
Verified
Journal Article
Open access
PDF file
DSDinara I. Sadykova
Dinara I. Sadykova
KSKarina Salakhova
Karina Salakhova
LGLiliya F. Galimova
Liliya F. Galimova
ESEvgeniia Slastnikova
Evgeniia Slastnikova
CKChulpan D. Khaliullina
Chulpan D. Khaliullina
ЧХЧ. Д. Халиуллина
Ч. Д. Халиуллина
Cardiovascular diseases are the leading cause of disability and mortality worldwide. Cardiovascular mortality rate is steadily increasing despite the large-scale preventive measures. Familial hypercholesterolemia is the most common genetically determined disorder of lipid metabolism as the major cause of blood circulatory system diseases development and progression. Worldwide, there are 6.8–8.5 million children with this primary dyslipidemia. Early (in childhood) diagnosis of familial hypercholesterolemia is crucial for the timely initiation of lipid-lowering therapy in order to reduce the atherosclerosis progression and the risk of life-threatening cardiovascular events. New screening programs have been implemented, new biomarkers of the disease have been studied, and lipid-lowering drugs with new mechanisms of hypolipidemic action have been developed to increase the efficacy of these activities in economically developed countries.

3 July 2020 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Closed access
LGL. F. Galimova
L. F. Galimova
DSD. I. Sadykova
D. I. Sadykova
ESEvgeniia Slastnikova
Evgeniia Slastnikova
NUN. E. Usova
N. E. Usova
Aim. To conduct a cascade screening and to assess its effectiveness in the diagnosis of familial hypercholesterolemia (FH) in children.Material and methods. The study was conducted from January 2017 to August 2018 on the basis of the City Clinical Hospital № 7 and the Children’s Republican Clinical Hospital (Kazan, the Republic of Tatarstan). It consisted of identifying index cases — primary patients with FH with further examination of first- and second-degree relatives <18 years old. In adults, the diagnosis was established according to Dutch Lipid Clinic Network (DLCN) criteria): FH was diagnosed with a score of ≥6. In children and adolescents 5 mmol/L were selected. Next, a targeted screening was carried out aimed at the diagnosis of FH, as a result of which 61 index patients were identified. At the next stage, as a part of cascade screening, 87 first- and second-degree relatives <18 years old were examined. In 43 (49,4%) children, heterozygous HF was diagnosed, of which in 4 patients the disease was detected by re-examination after 1 year.Conclusion. Cascade screening is a necessary and effective method for the diagnosis of АР in first- and second-degree relatives <18 years old. All children of the index patients should be monitored or genetic testing necessary to rule out FH. Today, it is important to increase awareness among clinicians about the diagnosis of FH in adults and children.